Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients

Bystrický, Branislav; Čierna, Zuzana; Sieberova, Gabriela; Janega, Pavol; Karaba, Marián; Minárik, Gabriel; Benca, Juraj; Sedláčková, Tatiana; Jurišová, Silvia; Gronesova, Paulina; Pinďák, Daniel; Macuch, Jan; Mardiak, Jozef; Mego, Michal

doi:10.21873/anticanres.11624

Cited by 11 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These vimentin-positive/cytokeratin-negative cells might be cancer cells that have undergone epithelial-to-mesenchymal transition, although the absence of cytokeratin expression suggests that they are likely to be fibroblast-like cells (CTCs are typically defined as cytokeratin-positive). Interestingly, stromal annexin A2 expression was higher in the tumours of patients who had a majority of CTCs with a mesenchymal phenotype than in those with a majority of epithelial-like CTCs 156 . These data suggest that circulating CAFs might have a role in the metastatic process, as they are found in patients with metastatic disease at a higher rate than those with localized disease.…”

Section: Stroma–cancer Interactionsmentioning

confidence: 93%

Targeting the tumour stroma to improve cancer therapy

2018

View full text Add to dashboard Cite

Cancers are not merely composed of cancer cells alone and, instead, are complex ‘ecosystems’ comprising many different cell types and noncellular factors. The tumour stroma is a critical component of the tumour microenvironment, where it has crucial roles in tumour initiation, progression, and metastasis. Most anticancer therapies target cancer cells specifically, but the tumour stroma can promote resistance of cancer cells to such therapies, eventually resulting in fatal disease. Therefore, novel treatment strategies should combine anticancer and antistroma agents. Herein, we provide an overview of the advances in understanding the complex cancer cell–tumour stroma interactions, and discuss how this knowledge can result in more effective therapeutic strategies, which might ultimately improve patient outcomes.

show abstract

Section: Stroma–cancer Interactionsmentioning

confidence: 93%

Targeting the tumour stroma to improve cancer therapy

2018

View full text Add to dashboard Cite

show abstract

“…Survival analysis reveals substantially poor OS and DFS in patients with high Anxa2 expression 8 . Anxa2 could also be a secretory biomarker in the plasma samples of patients with breast cancer and thus is valuable for early diagnosis 9,10 . The triple negative (ER, PR, and HER2 negative) breast cancer (TNBC) is the most aggressive type usually detected with upregulated EGFR expression, and Anxa2 is reversely correlated with hormone receptors 11 and HER2 expression 12 but positively related with EGFR expression in breast cancer tissues 8 .…”

Section: Breast Cancermentioning

confidence: 99%

Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism

Wang

Niu

et al. 2019

Cancer Biol Med

View full text Add to dashboard Cite

Anxa2 is the most studied member of the calcium-mediated phospholipid-binding protein family annexins and is a biomarker in cancers. In this review, we listed clinical findings and confirmed the value of Anxa2 in early diagnosis and prognostic prediction due to its overexpression and adverse effect on the outcome in most tumors. Anxa2 plays a pivotal role in cancer cell proliferation, migration, invasion, metastasis, and treatment resistance. Improved understanding of its cancer-promoting function might make it an ideal target for cancer therapy. Here, we systematically summarized the mechanism of Anxa2 in regulating epithelial-mesenchymal transition (EMT), cytoskeleton dynamicity, cell cycle, apoptosis, angiogenesis, and immunology by using various tumor models. These data emphasize the potential of Anxa2 for targeted intervention in tumors. Altering Anxa2 expression, neutralizing the cell surface Anxa2, or inhibiting its activation, such as through Tyr23 phosphorylation, could be considered based on the regulatory mechanism of Anxa2 in tumor progression.

show abstract

“…In 2016, Mangala et al described the selection of thioaptamers targeting ovarian cancer-associated endothelial cells generated by using a thioaptamer version of the Cell-SELEX technique [ 155 ] against ovarian cancer associated-endothelial cells derived from ten different patients while using cells derived from normal ovaries as controls. They found that the Endo28 thioaptamer targets annexin A2, a protein upregulated in cancer [ 156 , 157 ]. When Endo28 was conjugated to the surface of Chitosan (CH) Nanoparticles (NP) containing siRNA targeting micro-RNAs miR106b-5p and miR30c-5p, the CH/Endo28-siRNA-NP provided enhanced targeting of the tumor relative to other organs.…”

Section: Thioaptamer Developmentmentioning

confidence: 99%

Development of Phosphorothioate DNA and DNA Thioaptamers

Volk

Lokesh

2017

Biomedicines

View full text Add to dashboard Cite

Nucleic acid aptamers are short RNA- or DNA-based affinity reagents typically selected from combinatorial libraries to bind to a specific target such as a protein, a small molecule, whole cells or even animals. Aptamers have utility in the development of diagnostic, imaging and therapeutic applications due to their size, physico-chemical nature and ease of synthesis and modification to suit the application. A variety of oligonucleotide modifications have been used to enhance the stability of aptamers from nuclease degradation in vivo. The non-bridging oxygen atoms of the phosphodiester backbones of RNA and DNA aptamers can be substituted with one or two sulfur atoms, resulting in thioaptamers with phosphorothioate or phosphorodithioate linkages, respectively. Such thioaptamers are known to have increased binding affinity towards their target, as well as enhanced resistance to nuclease degradation. In this review, we discuss the development of phosphorothioate chemistry and thioaptamers, with a brief review of selection methods.

show abstract

Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients

Abstract: ANXA2 stromal expression might play a key role in aggressive tumor phenotype associated with increased EMT CTCs release, however, other factors beyond ANXA2 are responsible for coagulation activation mediated by CTCs in breast cancer patients.

Cited by 11 publications

References 35 publications

Targeting the tumour stroma to improve cancer therapy

Targeting the tumour stroma to improve cancer therapy

Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism

Development of Phosphorothioate DNA and DNA Thioaptamers

Contact Info

Product

Resources

About